Clinical trials: Flavivirus Infections
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia
The purpose of this study was to demonstrate that different CYD dengue vaccine lots manufactured using the same method and in the same location but at different times produce an equivalent immunological response after 3 doses.
- Trial name
- NCT01134263
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus
- Where
- 8 sites in Australia
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06579755
- Testing
- TDV
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Takeda
Zika Virus
Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection
In this prospective observational study the investigators will report on 20 male subjects with proven WHO-classification Zika infection.
- Trial name
- NCT02979938
- Testing
- Semen analysis and semen PCR for Zika virus
- Where
- Trinidad and Tobago
- Volunteers
- 25 people
- Sponsor
- Trinidad and Tobago IVF and Fertility Centre
Yellow Fever
Turnover of Antigen Specific Lymphocytes and Monocytes After Immunization With the 17D Yellow Fever Vaccine
The yellow fever vaccine is a live, attenuated virus that results in a robust immune response, especially in the T cell compartment.
- Trial name
- NCT01290055
- Testing
- Yellow fever vaccine, Deuterium (70% enriched 2H2O) labeled water
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Sri Edupuganti
Yellow Fever (Healthy Volunteers), Biopsy/Methods
Baseline Assessment of Skin Resident Memory T Cells in Healthy Unvaccinated Participants
In The main GeKoSkimm trial (= A randomized controlled trial to compare the immunogenicity and skin imprinting of intradermal, subcutaneous and intramuscular yellow fever vaccination) the investigators try to understand whether…
- Trial name
- NCT07636551
- Testing
- Skin punch biopsy, Blood samples
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Tick-Borne Encephalitis
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
Tick-borne encephalitis (TBE) is a viral illness common in the Northern Hemisphere, especially Europe and Asia. TBE infection may lead to central nervous system problems and death.
- Trial name
- NCT00118924
- Testing
- LGT(TP21)/DEN4
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia
The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination.
- Trial name
- PRIME-Q (NCT06388785)
- Testing
- No Intervention
- Where
- 2 sites in Malaysia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Tick-borne Encephalitis, France
Evaluation of Knowledge on Tick-borne Encephalitis Virus (TBEV) Infection Among General Practitioners in France
Tick-borne encephalitis is a relatively rare disease (approximately 35 cases diagnosed per year), but most cases (86%) are due to contamination in France via a tick bite.
- Trial name
- CoMTBEV (NCT07191223)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Dengue
Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).
Dengue is one of the most epidemiologically and clinically relevant arboviral diseases, affecting half of the global population.
- Trial name
- RIMVADE (NCT07158190)
- Testing
- Vaccine
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Dengue
Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
This is a randomized, multicenter, double-blind, placebo-controlled Phase III study that will evaluate efficacy and safety of a live attenuated, tetravalent, lyophilized dengue vaccine produced by Butantan Institute.
- Trial name
- NCT02406729
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 17 sites in Brazil
- Volunteers
- 16,935 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Zika Virus
Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge
Zika virus (ZIKV) is an illness people can get from mosquitoes. The infection is generally mild with symptoms that include a fever, rash, red eyes, and joint pain, though most of those infected have no symptoms.
- Trial name
- NCT06805487
- Testing
- TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier
Encephalitis, Tick-Borne
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
The main purpose of this study is to assess the seropersistence of TBE virus antibodies in children, adolescents and young adults who received the first booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5…
- Trial name
- NCT00894686
- Testing
- FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Pfizer
Zika Virus, Zika Virus Infection
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
This was a multicenter, randomized study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo.
- Conditions
- Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections
- Trial name
- DNA (NCT03110770)
- Testing
- VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP
- Where
- 17 sites in United States, Brazil and 7 more
- Volunteers
- 2,428 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tick Borne Encephalitis (TBE)
An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE
This study will evaluate the durability of antibody responses in children and adolescents after primary immunization with TBE vaccine
- Trial name
- NCT01106482
- Testing
- Serology blood draw
- Where
- 10 sites in Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Dengue
Insecticidal School Uniforms for Dengue Prevention in Thailand
This is a randomised controlled trial that will be conducted in eastern Thailand in a group of schools with approximately 2,000 students aged 7-15 years.
- Trial name
- DengueTools (NCT01563640)
- Testing
- permethrin insecticide, washing
- Where
- Thailand
- Volunteers
- 1,825 people, healthy volunteers welcome
- Sponsor
- Umeå University
Dengue Virus, Dengue Fever
Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
This is part of an ongoing effort to develop a satisfactory dengue vaccine: Primary objective: To describe the safety after each vaccination with bivalent and tetravalent formulations of dengue vaccine candidates.
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00740155
- Testing
- Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero), Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero), Tetravalent CYD-1,2,3,4 Dengue (Vero)
- Where
- 2 sites in Mexico
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Virus, Zika, Zika Virus Disease
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants
The purpose of this study is to describe the safety, tolerability and immunogenicity of two doses of purified inactivated Zika virus vaccine (PIZV) given 28 days apart.
- Conditions
- Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
- Trial name
- NCT03343626
- Testing
- PIZV
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Takeda
Encephalitis, Tick-borne
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
The objective of this study is to assess the TBE antibody persistence approximately three years after administration of a TBE booster vaccination with FSME-IMMUN 0.25 ml Junior in children who received either 0.25 mL or 0.5 mL…
- Trial name
- NCT00163618
- Testing
- Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
- Where
- 4 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer